購物車 
-
Ascidiacyclamide
- names：
Ascidiacyclamide
- CAS號：
86701-12-4
MDL Number： - MF(分子式)： C36H52N8O6S2 MW(分子量)： 756.982
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計 (￥) |
|---|
| 中文別名 | (4S,7R,8S,11R,18S,21R,22S,25R)-4,18-bis[(2S)-butan-2-yl]-7,21-dimethyl-11,25-di(propan-2-yl)-6,20-dioxa-13,27-dithia-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),12(31),14,19(30),26(29)-hexaene-2,9,16,23-tetrone |
| 英文別名 | Ascidiacyclamide |
| CAS號 | 86701-12-4 |
| Inchi | InChI=1S/C36H52N8O6S2/c1-11-17(7)25-33-43-27(19(9)49-33)31(47)39-24(16(5)6)36-38-22(14-52-36)30(46)42-26(18(8)12-2)34-44-28(20(10)50-34)32(48)40-23(15(3)4)35-37-21(13-51-35)29(45)41-25/h13-20,23-28H,11-12H2,1-10H3,(H,39,47)(H,40,48)(H,41,45)(H,42,46)/t17-,18-,19+,20+,23+,24+,25-,26-,27-,28-/m0/s1 |
| InchiKey | QBRRPBPLIGDANJ-AXCFFLBZSA-N |
| 分子式 Formula | C36H52N8O6S2 |
| 分子量 Molecular Weight | 756.982 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說明 | Ascidiacyclamide(CAS:86701-12-4):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Ascidiacyclamide is a cytotoxic cyclic peptide from the marine tunicate Ascidian. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Jaspars M. The origins of cyanobactin chemistry and biology. Chem Commun (Camb). 2014 Sep 14;50(71):10174-6. doi: 10.1039/c3cc49252d. Review. PubMed PMID: 25068542. |
| [2]Comba P, Gahan LR, Hanson GR, Maeder M, Westphal M. Carbonic anhydrase activity of dinuclear Cu(II) complexes with patellamide model ligands. Dalton Trans. 2014 Feb 28;43(8):3144-52. doi: 10.1039/c3dt53135j. PubMed PMID: 24326405. |
| [3] Asano A, Minoura K, Yamada T, Doi M. Conformational transformation of ascidiacyclamide analogues induced by incorporating enantiomers of phenylalanine, 1-naphthylalanine or 2-naphthylalanine. J Pept Sci. 2016 Mar;22(3):156-65. doi: 10.1002/psc.2853. PubMed PMID: 26856689. |
| [4] Asano A, Yamada T, Doi M. Modulating the structure of phenylalanine-incorporated ascidiacyclamide through fluorination. J Pept Sci. 2014 Oct;20(10):794-802. doi: 10.1002/psc.2668. Epub 2014 Jul 1. PubMed PMID: 24985333. |
| [5] Asano A, Doi M, Kobayashi K, Arimoto M, Ishida T, Katsuya Y, Mezaki Y, Hasegawa H, Nakai M, Sasaki M, Taniguchi T, Terashima A. Effects of amino acids and chirality for molecular folding of desoxazoline-ascidiacyclamide derivatives: X-ray crystal structures of four cyclic octapeptides including unusual amino acids, cyclo(-Ile-aThr-D-Val-Thz-)(2), cyclo(-Ala-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), cyclo(-Val-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), and cyclo(-Ile-aThr-Val-Thz-Ile-aThr-D-Val-Thz-). Biopolymers. 2001 Mar;58(3):295-304. PubMed PMID: 11169389. |
6: Asano A, Numata S, Yamada T, Minoura K, Doi M. Conformational properties of ascydiacyclamide analogues with cyclic α-amino acids instead of oxazoline residues. Bioorg Med Chem. 2017 Dec 15;25(24):6554-6562. doi: 10.1016/j.bmc.2017.10.029. Epub 2017 Oct 26. PubMed PMID: 29097029.7: Doi M, Shinozaki F, In Y, Ishida T, Yamamoto D, Kamigauchi M, Sugiura M, Hamada Y, Kohda K, Shioiri T. Conformational change of ascidiacyclamide caused by asymmetric modification for an isoleucine residue: structural analyses of [Gly], [Leu], and [Phe]ascidiacyclamides by x-ray diffraction and NMR spectroscopy. Biopolymers. 1999 May;49(6):459-69. PubMed PMID: 10193193.8: Asano A, Yamada T, Doi M. The square conformation of phenylglycine-incorporated ascidiacyclamide is stabilized by CH/π interactions between amino acid side chains. Bioorg Med Chem. 2011 Jun 1;19(11):3372-7. doi: 10.1016/j.bmc.2011.04.036. Epub 2011 Apr 22. PubMed PMID: 21592800.9: Asano A, Yamada T, Numata A, Doi M. Cyclo(-Cha-Oxz-D-Val-Thz-Ile-Oxz-D-Val-Thz-) N,N-dimethylacetamide dihydrate: a square form of cyclohexylalanine-incorporated ascidiacyclamide having the strongest cytotoxicity. Acta Crystallogr C. 2003 Sep;59(Pt 9):o488-90. Epub 2003 Aug 9. PubMed PMID: 12944653.10: Ishida T, In Y, Doi M, Inoue M, Hamada Y, Shioiri T. Molecular conformation of ascidiacyclamide, a cytotoxic cyclic peptide from Ascidian: X-ray analyses of its free form and solvate crystals. Biopolymers. 1992 Feb;32(2):131-43. PubMed PMID: 1637988.1
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養(yǎng)基內(nèi)，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域，封口膜是保障實驗準確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設計用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實驗室中是通用的，可用于蛋白質(zhì)印跡、細胞組織培養(yǎng)、P...
2022/10/19 9:39:51
